93 related articles for article (PubMed ID: 28018925)
1. Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children.
Kajubi R; Huang L; Were M; Kiconco S; Li F; Marzan F; Gingrich D; Nyunt MM; Ssebuliba J; Mwebaza N; Aweeka FT; Parikh S
Open Forum Infect Dis; 2016 Oct; 3(4):ofw217. PubMed ID: 28018925
[TBL] [Abstract][Full Text] [Related]
2. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
[TBL] [Abstract][Full Text] [Related]
3. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
Huang L; Carey V; Lindsey JC; Marzan F; Gingrich D; Graham B; Barlow-Mosha L; Ssemambo PK; Kamthunzi P; Nachman S; Parikh S; Aweeka FT;
PLoS One; 2017; 12(10):e0186589. PubMed ID: 29065172
[TBL] [Abstract][Full Text] [Related]
4. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Kay K; Goodwin J; Ehrlich H; Ou J; Freeman T; Wang K; Li F; Wade M; French J; Huang L; Aweeka F; Mwebaza N; Kajubi R; Riggs M; Ruiz-Garcia A; Parikh S
Clin Pharmacol Ther; 2023 Mar; 113(3):660-669. PubMed ID: 36260349
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
[TBL] [Abstract][Full Text] [Related]
7. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
[TBL] [Abstract][Full Text] [Related]
8. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
[TBL] [Abstract][Full Text] [Related]
9. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
Huang L; Parikh S; Rosenthal PJ; Lizak P; Marzan F; Dorsey G; Havlir D; Aweeka FT
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):310-6. PubMed ID: 22918158
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Okaba-Kayom V; Mayanja-Kizza H; Katabira E; Hanpithakpong W; Pakker N; Dorlo TP; Tarning J; Lindegardh N; de Vries PJ; Back D; Khoo S; Merry C
J Antimicrob Chemother; 2012 May; 67(5):1217-23. PubMed ID: 22316571
[TBL] [Abstract][Full Text] [Related]
11. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
Kakuru A; Achan J; Muhindo MK; Ikilezi G; Arinaitwe E; Mwangwa F; Ruel T; Clark TD; Charlebois E; Rosenthal PJ; Havlir D; Kamya MR; Tappero JW; Dorsey G
Clin Infect Dis; 2014 Aug; 59(3):446-53. PubMed ID: 24759826
[TBL] [Abstract][Full Text] [Related]
12. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
[TBL] [Abstract][Full Text] [Related]
13. Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by
Abdullahi ST; Soyinka JO; Olagunju A; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Winterberg M; Tarning J; Owen A; Khoo S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871092
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.
Yeka A; Lameyre V; Afizi K; Fredrick M; Lukwago R; Kamya MR; Talisuna AO
PLoS One; 2014; 9(12):e113311. PubMed ID: 25436614
[TBL] [Abstract][Full Text] [Related]
15. The effect of lopinavir/ritonavir on the antimalarial activity of artemether or artemether/lumefantrine in a mouse model of Plasmodium berghei.
Abiodun OO; Akinbo J; Ojurongbe O
J Chemother; 2015 Feb; 27(1):25-8. PubMed ID: 24621166
[TBL] [Abstract][Full Text] [Related]
16. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.
WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group
BMC Med; 2015 Sep; 13():227. PubMed ID: 26381375
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria.
Salman S; Bendel D; Lee TC; Templeton D; Davis TM
Antimicrob Agents Chemother; 2015; 59(6):3208-15. PubMed ID: 25801552
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
Ezzet F; Mull R; Karbwang J
Br J Clin Pharmacol; 1998 Dec; 46(6):553-61. PubMed ID: 9862244
[TBL] [Abstract][Full Text] [Related]
20. Artemether-lumefantrine for uncomplicated malaria: a systematic review.
Omari AA; Gamble C; Garner P
Trop Med Int Health; 2004 Feb; 9(2):192-9. PubMed ID: 15040555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
